14 Folgen

Blood cancers are complex and multifaceted diseases, requiring knowledge by healthcare professionals on the array of diagnostic tests, treatment therapies, and survivorship issues. The LLS Podcast Series for Professionals provides up to date and accurate information on diagnosis, treatment and survivorship to educate HCPs treating patients with blood cancer. Listen in as we speak with experts who will guide us in understanding these topics, as well as address the importance of clinical trials, side effects management, and other concerns.

Treating Blood Cancer‪s‬ The Leukemia & Lymphoma Society

    • Wissenschaft

Blood cancers are complex and multifaceted diseases, requiring knowledge by healthcare professionals on the array of diagnostic tests, treatment therapies, and survivorship issues. The LLS Podcast Series for Professionals provides up to date and accurate information on diagnosis, treatment and survivorship to educate HCPs treating patients with blood cancer. Listen in as we speak with experts who will guide us in understanding these topics, as well as address the importance of clinical trials, side effects management, and other concerns.

    Managing Treatment for Patients with Relapsed/Refractory Lymphoma

    Managing Treatment for Patients with Relapsed/Refractory Lymphoma

    Sonali M. Smith, MD, FASCO, The University of Chicago, Chicago, IL















    Recorded on January 25, 2021







    How do we start the conversation? How do we discuss patient expectation and the likelihood of relapse? What role does the timing of relapse play? In this episode, Dr. Sonali Smith, the Elwood V. Jensen Professor of Medicine at The University of Chicago, discusses expectations for disease control and for relapse, the mechanisms of resistance, exciting advances in the treatment of relapsed/refractory lymphoma, including new treatments, and so much more. Tune in to this important talk today!











    Sonali Smith, MD, FASCO

    Elwood V. Jensen Professor of Medicine

    Chief, Section of Hematology/Oncology

    Co-Leader, Cancer Service Line

    Co-Director, Lymphoma Program

    The University of Chicago

    Chicago, IL





    This podcast episode is supported by Epizyme.

    • 31 Min.
    What’s New in Treatment for Acute Myeloid Leukemia (AML)

    What’s New in Treatment for Acute Myeloid Leukemia (AML)

    Olatoyosi Odenike, MD and Wendy Stock, MD















    Recorded on January 15, 2021







    Join Drs. Wendy Stock and Olatoyosi Odenike from The University of Chicago Medicine, in an important discussion on the progress in the treatment of acute myeloid leukemia, including important updates from the LLS Beat AML Master Trial. Drs. Stock and Odenike talk with Dr. Ken Miller about determining a treatment plan for each patient, the role genetics and epigenetics may play, what the ultimate goals of care are, including having difficult conversations with patients regarding treatment, and monitoring for measurable residual disease and maintenance therapy. Be a part of the conversation today!













    Olatoyosi Odenike, MDProfessor of MedicineDirector, Leukemia ProgramSection of Hematology/OncologyThe University of Chicago MedicineChicago, IL











    Wendy Stock, MDAnjuli Seth Nayak Professor of Leukemia ResearchThe University of Chicago MedicineChicago, IL

    • 39 Min.
    Progress in the Treatment of Follicular Lymphoma

    Progress in the Treatment of Follicular Lymphoma

    Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR















    Recorded on December 14, 2020





    What is follicular lymphoma and how does it differ from other indolent lymphomas? Can this cancer be cured? Join Dr. Ken Miller as he speaks with Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute and Medical Director of Hematology Research for The US Oncology Network to discuss this disease. Dr. Sharman reviews the current treatment options as well as upcoming treatment approaches, including the latest from research presented at the 2020 American Society of Hematology (ASH) Annual Meeting.

    Jeff Sharman, MD

    Director of Research

    Willamette Valley Cancer Institute

    Medical Director of Hematology Research

    The US Oncology Network

    Eugene, OR





    This podcast episode is supported by Epizyme.

    • 27 Min.
    Current Applications of Cancer Genomics: Focus on CLL

    Current Applications of Cancer Genomics: Focus on CLL

    Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA















    Recorded on November 19, 2020





    Morphology was once the only means of classifying blood cancers especially CLL; flow cytometry, cytogenetics and immunohistochemistry all followed. With a revolution in understanding, there is now a growing list of molecular tests that provide even more precise diagnostic and prognostic tools in diagnosis and treatment decisions. In this episode, Dr. Ken Miller speaks with Dr. Jennifer Brown from the Dana-Farber Cancer Institute about cancer genomics, its current applications in diagnosis, prognosis, treatment decisions, risk of recurrence, and the future of genomics testing in hematologic malignancies. Tune in to this informative conversation today!

    Jennifer Brown, MD, PhD

    Director, CLL Center

    Dana-Farber Cancer Institute

    Professor of Medicine, Harvard Medical School

    Institute Physician

    Dana-Farber Cancer Institute

    Boston, MA





    This podcast episode is supported by Foundation Medicine, Inc.

    • 33 Min.
    Supporting LGBTQI Cancer Patients

    Supporting LGBTQI Cancer Patients

    Matthew B. Schabath, PhD, Moffitt Cancer Center, Tampa, FL















    Recorded on November 2, 2020





    Individuals in the LGBTQI community face many barriers in accessing healthcare. In this episode, Dr. Matthew Schabath from the Moffitt Cancer Center addresses ways healthcare professionals can be more competent in supporting persons within this community. Dr. Schabath breaks down the terminology and stakeholders within this group to help make conversations comfortable and more productive with patients and their caregivers, discusses an overview of COLORS training and its importance, and describes how best to include caregivers and loved ones in patient care. Join this important conversation today!

    Matthew B. Schabath, PhD

    Associate Member in Cancer Epidemiology

    Moffitt Cancer Center

    Tampa, FL

    • 27 Min.
    A Deeper Dive into MRD: A Conversation with Gail Roboz, MD

    A Deeper Dive into MRD: A Conversation with Gail Roboz, MD

    Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY















    Recorded on October 2, 2020





    Minimal/measurable residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this detection can be helpful. Dr. Roboz provides strategies to communicate with patients about the impact of MRD on prognosis, treatment and outcomes and discusses the future of MRD testing in blood cancers. Tune in today!

    Gail J. Roboz, MD

    Director, Clinical and Translational Leukemia Programs

    Professor of Medicine

    Weill Cornell Medical College

    The New York Presbyterian Hospital New York, NY





    This podcast episode is supported by Amgen.

    • 45 Min.

Top‑Podcasts in Wissenschaft

Zuhörer haben auch Folgendes abonniert: